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ABSTRACT 
Purpose Up to 50% of urinary tract infections (UTIs) in young children are missed in primary care. Urine 
culture is essential for diagnosis, but urine collection is often difficult. Our aim was to derive and internally 
validate a two-step clinical rule using (1) symptoms and signs to select children for urine collection; and (2) 
symptoms, signs and dipstick testing to guide antibiotic treatment. 
Methods We recruited acutely unwell children <5 years from 233 primary care sites across England and 
Wales. Index tests were parent reported symptoms; clinician reported signs; urine dipstick results; and 
clinician opinion of UTI likelihood (‘clinical diagnosis’ prior to dipstick and culture). The reference standard 
was microbiologically confirmed UTI cultured from a clean catch urine sample. We calculated sensitivity, 
specificity and area under the receiver operator characteristic (AUROC) curve of coefficient-based (graded 
severity) and points-based (dichotomised) symptom/sign logistic regression models and internally validated 
the AUROC using bootstrapping. 
Results 3036 children provided urines and culture results were available for 2740 (90%). Of these 60 (2.2%) 
were positive: ‘clinical diagnosis’ was 46.6% sensitive with AUROC of 0.77. Previous UTI, increasing 
pain/crying on passing urine, increasingly smelly urine, absence of severe cough, increasing clinician 
impression of severe illness, abdominal tenderness on examination and normal ear examination were 
associated with UTI. The validated coefficient (points) based model AUROCs were 0.87 (0.86), increasing to 
0.90 (0.90) by adding dipstick nitrites, leucocytes and blood. 
Conclusions A symptoms and signs based clinical rule is superior to clinician diagnosis and performs well for 
identifying young children for non-invasive urine sampling. Dipstick results add further diagnostic value for 
empiric antibiotic treatment. 
 
Words 265  
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INTRODUCTION 
The accurate and timely diagnosis of urinary tract infection (UTI) in children is important to alleviate short-
term suffering1 and prevent the possible long-term consequences such as renal scarring, impaired renal 
growth, recurrent pyelonephritis, impaired glomerular function, hypertension, end stage renal disease, and 
pre-eclampsia.2 3 4 Guidelines universally recommend urine sampling for microbiological confirmation, by 
clean catch (preferred in Europe),5 or catheterization or suprapubic aspiration (SPA) for unwell children 
where clean catch is not immediately available (preferred in the US6 and Australia7).   
There are three possible explanations why half of UTIs are not diagnosed at the earliest opportunity in UK 
primary care.8 First, there is a paucity of primary care relevant evidence regarding which children should be 
suspected. Guidelines, which emphasise the importance of fever,6 7 9 are largely informed by studies 
conducted in emergency departments.10 11 12 Second, the symptoms and signs of UTI are often non-specific, 
especially in very young children. Finally, obtaining an uncontaminated sample can be challenging, time-
consuming, and for invasive catheter and SPA sampling methods, painful,13 frightening14 and induce 
infection.15 
We report a large, prospective cohort study designed to investigate the diagnostic features of UTI in young 
children presenting to primary care. Our aim was to develop and internally validate a two-step clinical rule: 
step 1 used symptoms and signs to select children for urine sampling and step 2 (once urine was obtained) 
used symptoms, signs and dipstick testing to guide empiric antibiotic treatment. ‘Coefficient’ and ‘points’ 
based clinical rules were developed for use with and without computer assistance. 
 
 
 
 
  
 5 
METHODS 
Design 
‘DUTY’ was a multicenter, prospective, diagnostic cohort study recruiting children presenting to National 
Health Service (NHS) primary care sites. General Practitioners (GPs), nurses and children’s emergency 
department (CED) doctors (from here on ‘clinicians’) working in primary care sites (GP clinics, CEDs and 
Walk-in Centres) are the clinicians who provide primary care for children. Primary care sites were recruited 
and trained by four UK centre hubs (Bristol, Cardiff, London and Southampton).  
Participants  
Children were eligible if presenting with any acute (<28 days) illness episode, where the illness was 
associated with: (a) at least one constitutional symptom or sign identified by the National Institute of 
Health and Clinical Excellence (NICE)5 as a potential marker for UTI (fever, vomiting, lethargy/malaise, 
irritability, poor feeding and failure to thrive); and/or (b) at least one urinary symptom identified by NICE5 
as a potential marker of UTI (abdominal pain, jaundice (children <3 months only), hematuria, offensive 
urine, cloudy urine, loin pain, frequency, apparent pain on passing urine and changes to continence). As a 
result, constitutionally unwell children consulting with an apparently obvious cause for their symptoms 
(such as acute otitis media or bronchiolitis, without a urinary symptom) were included. Children were 
excluded if: constitutionally well (e.g. acute conjunctivitis only); neurogenic or surgically reconstructed 
bladder; permanent or intermittent urinary catheter; trauma as the main presenting problem; or antibiotics 
had been taken within seven days. Clinicians, aided by research nurses where available, were asked to 
recruit consecutive eligible children and where this was not possible to log children’s age and gender (Web 
Figure 1). 
Index tests and urine collection 
Following consent, 107 index tests (symptoms, signs and dipstick results, Web Table 1) were recorded on a 
standardised Case Report Form by qualified clinicians blind to the reference standard. Parent-reported 
items included the child’s medical history and symptoms. Signs, from a full clinical examination, included 
clinicians’ global illness severity impression (zero to ten) and abdominal tenderness. Before urine dipstick 
testing, clinicians recorded their rating of UTI likelihood (‘clinical diagnosis’). 
Our preferred urine collection method was ‘clean catch’. For toilet trained children, we used a sterile bowl 
that the parent could hold under the child or put in a potty. For other children, the parent cleaned the 
diaper (nappy) area using water alone and sat the child on their knee with the bowl placed under their 
perineum. If it was not possible to obtain a sample at the site, the parent was given equipment and advice 
on taking the sample at home. Where clean catch was not feasible, we used NICE-recommended 
‘Newcastle Nappy Pads’ (a sterile pad placed inside the diaper),5 but because of differences in 
contamination rates and children’s ages between clean catch and diaper pad samples, the current analysis 
focuses on clean catch samples. 
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Urine samples were tested at the site using Siemans/Bayer multistix 8SG dipsticks. Urine samples were split 
into two fractions for microbiological analysis. The priority fraction was sent to the site’s usual laboratory. 
When at least 1ml was left, the remainder was sent using first class postal SafeboxesTM in boric acid 
monovettes to the Public Health Wales Microbiology Specialist Antimicrobial Chemotherapy Unit in Cardiff 
(the “research laboratory”). 
Reference standard  
The reference standard was determined at the research laboratory, which spiral plated (Don Whitley, 
United Kingdom (UK)) 50μL of urine onto chromogenic agar and standard blood agar. Quantitative total 
counts were recorded for up to six organisms and the presence of antimicrobial substances measured. 
Samples were processed by two staff members using a single, standardised procedure. As per UK 
guidelines,16 our microbiological definition of UTI was either the ‘pure’ (single) or ‘predominant’ growth of a 
uropathogen (an Enterobacteriaceae) at ≥105 Colony Forming Units (CFU)/mL. We defined ‘predominant’ 
growth as ≥105 CFU/mL of a uropathogen with ≥3 log10 (1000-fold) difference between the growth of this 
and the next species. For comparison, we used the United States (US) definition6 of a pure uropathogen 
growth >50,000 CFU/ml with ≥25 white blood cells/mm3 on microscopy or leucocyte positive (threshold at 
nil/trace) on dipstick. 
Sample size calculation  
We assumed a candidate predictor prevalence of 10% and UTI prevalence of 2%.17 With 80% power and a 
two-sided alpha of 5%, 3000 urine results were required to detect an odds ratio of 2.4 while 3100 results 
would give a clinical rule with 80% sensitivity a 95% CI width of 10%. We originally proposed to recruit 4000 
children with a target of recovering urines from at least 3,100 (77.5%) for clinical rule derivation and a 
further 2000 children for external validation. However, we did not anticipate the need to stratify analyses 
by clean catch/diaper pad collection method. We therefore decided to use all available clean catch results 
to derive the models, with internal bootstrap validation instead of external validation. 
Summary of tatistical analysis 
A full description of statistical methods is given in the Web Appendix. In summary, we first compared the 
age and gender of the children who were recruited with those children whose parents declined to 
participate. Then, using logistic regression, we estimated associations of index tests with urine culture 
positivity in two steps (reflecting clinical procedure): in step 1 we used symptoms and signs to select 
children for urine sampling and in step 2 (once urine was obtained) we used symptoms, signs and dipstick 
testing to guide empiric antibiotic treatment. ‘Coefficient’ and ‘points’ based clinical rules were developed 
for use with and without computer assistance. We quantified diagnostic accuracy using the area under the 
receiver operating characteristic (AUROC) curve with 95% confidence interval and internally validated 
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coefficient-based models using the bootstrap procedure described by Steyerberg.18 Since children 
presenting with ‘fever of unknown origin’ is a group of particular clinical interest, we investigated the 
presence of UTI among children identified as having fever without symptoms or signs suggestive of another 
source. To assess the added value of dipsticks over symptoms and signs alone we (i) quantified the change 
in AUROC and (ii) used a simulation procedure to calculate the change in the probability of UTI associated 
with addition of dipstick results. Finally, since UTI laboratory criteria differ between the UK and US, we 
calculated the prevalence and bias adjusted kappa statistic to assess agreement between UK and US UTI 
definitions19 and used crude and adjusted odds ratios, and the AUROC to assess strength of association, and 
diagnostic utility, of index tests identified as diagnostic using the UK UTI definition. 
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RESULTS 
Between April 2010 and April 2012, 516 staff (61 research nurses; 182 GPs; and 273 site nurses) recruited 
participants from 233 primary care sites (225 GP practices, four Walk-in centers and four CEDs) across 
England and Wales. Of 14724 children screened for eligibility, 4390 (43%) were ineligible, 1276 (12.6%) 
declined participation, 1880 (18.5%) could not be recruited for other reasons and 15 (0.15%) withdrew, 
leaving 7163 with valid consent and index test data (Web Figure 2), of whom 6797 (94.9%) were recruited 
in GP surgeries, 284 (4.0%) in CEDs and 82 (1.1%) in WICs. Urine was collected using diaper (nappy) pad 
from 3205 (reported in a separate paper20) and clean catch from 3036 children, with reference standard 
(research laboratory) results available for 2740 (90%) of clean catch samples. Of these, 2561 (93%) were 
two years or older and 1473 (54%) female (Table 1). The most common working diagnoses were upper 
respiratory tract infection (28%), viral illness (15%), otitis media (10%) and gastroenteritis (3.6%). One third 
of samples arrived at the research laboratory within 24 hours of collection. Transit time did not affect 
culture performance.21 
Sixty (2.2%) children met the laboratory definition for UTI: 50 (83.3%) with Escherichia coli; 5 (8.3%) with 
Proteus species; 3 (5.0%) with Klebsiella species; 1 (1.7%) with Morganella morganii and 1 (1.7%) with 
Citrobacter farmeri. 2627 (96%) samples were provided within 24 hours of index test measurement. Urinary 
antimicrobial substances were found in 128 (4.5%) samples and in 4 (6.7%) of the UTI positive samples. A 
‘clinical diagnosis’ of UTI prior to urine dipstick testing was made in 168 (6.1%) children, of whom 28 
(16.7%) were UTI positive. ‘Clinical diagnosis’ achieved 46.6% sensitivity, 94.7% specificity and AUROC 0.77 
(95% CI 0.71 to 0.83). Missing data and ‘not known’ responses were infrequent (Table 1).  
Step 1 - symptoms and signs 
The parent-reported index tests associated with UTI in crude (Table 1) and adjusted (Table 2) analyses were 
pain/crying while passing urine, smelly urine, previous UTI and absence of severe cough. For the first two, 
there was a graded association with increasing symptom severity. Clinician-reported index tests associated 
with UTI were increasing illness severity (graded association), abdominal tenderness and absence of ear 
abnormalities. None of the other index tests (Web Table 1) met our criteria for model inclusion, and there 
was no evidence of association for fever of unknown origin (Web Table 3) or prior illness duration (data not 
shown). 
The multiple imputation-based AUROC for the coefficient-based step 1 model was 0.89 (95% CI 0.85 to 
0.95, internally validated AUROC 0.88, Table 2, Figure 1). Table 3 (upper) shows diagnostic test 
characteristics (sensitivity, specificity, positive and negative predictive values, percentage of children 
defined as positive) according to a range of cutpoints for the symptoms and signs model (for any 
combination of symptoms and signs, the linear predictor is obtained by adding the coefficients 
corresponding to those categories to the constant term in Web Table 6). To achieve sensitivities of 70% (all 
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children with linear predictor ≥-2.729) or 85% (linear predictor ≥-3.717) with the step 1 model would 
require urine sampling in 6.8% to 17.6% of children; with corresponding positive predictive values of 22.6% 
to 10.6% and specificities of 94.6% to 83.9%. While the points-based model had a similar AUROC 0.86 (95% 
CI 0.81 to 0.90, validated 0.85, Web Table 2) to the coefficient-based model, other diagnostic parameters 
were inferior: using an 85.0% sensitivity (≥3 point cut-off) only increased the post-test probability to 6.9%, 
with a lower specificity (74.4%) and higher (26.9%) urine collection rate (Web Table 4, upper). Using a ≥5 
point cut-off (“any three of five” symptoms and signs) increased the post-test UTI probability to 17.7%, with 
increased specificity (94.6%) and reduced urine collection rate (6.4%), but at the expense of reduced 
sensitivity (51.7%, Web Table 4 (upper) and Figure 2).  
Urine samples were available for 88, 91 and 612 children <12, 12 to 23, and 24 to 35 months with 
laboratory confirmed UTI in 4, 2 and 16 of these children respectively (Table 1). The coefficient model 
performed well in children under 3 years, with similar estimated odds and AUROC (Web Table 5). 
Step 2 - symptoms, signs and dipstick testing 
Dipstick leukocytes, nitrites, and blood were strongly associated with UTI (Tables 1 and 2). The coefficient-
based, multiple imputation model AUROC was 0.93 (95% CI 0.90 to 0.97, validated 0.90), an increase of 
0.034 (p=0.009) when dipstick results were added to symptoms and signs (Table 2, Figure 1). If all children 
had a urine sample and dipstick test, the dipstick test results could maintain sensitivity at 80% while 
improving specificity from 88.3% to 93.8% and reducing the percentage of children treated with antibiotics 
from 13.2% to 7.8%, assuming immediate antibiotic use (Table 3). The points-based model AUROC was 0.90 
(95% CI 0.85 to 0.95, validated 0.89), and increased (by 0.045, p=0.003) when dipstick results were added 
to symptoms and signs (Table 4). Web Table 7 shows there was a substantial impact on the probability of 
UTI associated with addition of dipstick test results to the step 1 with a median change in post-dipstick test 
probability of UTI 9.9% (95% range 1.4% to 55.5%).  
Serious adverse events 
79 (1.1%) of the 7163 recruited children were hospitalized, three related to dipstick testing (two with UTI 
and one with diabetes).  
Effects of replacing US with UK UTI definition 
Data were available for all 2740 (100%) children, 35 (1.3%) of whom were UTI positive using the US UTI 
definition. We found good agreement (prevalence and bias adjusted kappa = 0.98), and crude and adjusted 
odds ratios were similar, comparing US and UK UTI definitions, showing the same graded associations, 
except for ‘severe cough’ (adjusted odds ratio 0.74 (0.23 to 2.37) US compared with 0.29 (0.09 to 0.97) UK, 
data available from the authors). Step 1 and step 2 diagnostic utilities were stable to the US definition, with 
validated AUROCs of 0.88 and 0.93 respectively.   
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DISCUSSION 
Summary of findings  
In a large cohort of young children presenting with acute illness to primary care, 2.2% of clean catch urine 
samples met the microbiological criteria for UTI. Based on data obtained from clean catch samples, we 
developed novel coefficient (for computer use) and points-based clinical rules to help clinicians identify 
children for urine sampling and antibiotic treatment with high diagnostic utility. For step 1, the coefficient-
based rule was diagnostically superior to the points-based rule, which in turn, was superior to clinical 
diagnosis. For step 2, dipstick testing was diagnostically superior to symptoms and signs alone (both 
coefficient and points-based rules), and was not diagnostically useful in children with the lowest UTI 
probability, in whom step 1 would not result in urine collection. 
Strengths and limitations  
To our knowledge, this is the largest and most rigorous diagnostic accuracy study of UTI in children under 
five years in primary care. The generalisability of the final sample is supported by the similarity between 
participating children and those invited but declining. We achieved high levels of data completeness across 
a large number of primary care sites and maintained blinding of recruiting staff to the reference standard. 
Index tests were measured according to routine clinical practice using standardised reporting forms and 
equipment, and nearly all were completed within 24 hours of urine sample retrieval, minimising disease 
progression bias. The low number of samples with antimicrobial substances minimises treatment paradox. 
Our reference standard was specific to common uropathogens, and excluded index tests. Two members of 
staff, blind to all index tests bar age, performed the microbiological cultures and interpreted results, using a 
standardised process in a single laboratory. Our broad eligibility criteria allowed us to identify previously 
unidentified clinical features useful for both increasing (smelly urine) and decreasing (absence of severe 
cough, normal ear examination) UTI probability, as well as demonstrate the absence of diagnostic utility of 
other features (such as fever, fever of unknown origin, vomiting, lethargy, irritability and poor feeding) 
widely believed5 6  to be diagnostically useful. Our results are stable using the more conservative US 
definition of UTI. 
The main limitation is the relatively small number of UTI diagnoses, especially in the youngest children, 
which impacted on three areas. First, we were not able to externally validate our rules. While external 
validation is desirable prior to clinical application, bootstrap validation takes account of model over-
optimism. By analogy, it is reasonable for clinical practice to change on the basis of a single, high-quality, 
well conducted randomised trial, though replication is desirable. That said, since we recruited from ‘first-
point-of-contact’ primary care sites, we consider it necessary to evaluate the rule’s performance prior to 
use in secondary care. Second, our rule development breached the widely quoted “10 events per candidate 
predictor”. However, this rule of thumb has little theoretical justification, has been shown to be 
conservative,22 and the consequences of variable selection are strongly dependent on the strength of 
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association of candidate predictors with the outcome. Here, predictors of UTI are biologically plausible and 
associations substantial. Finally, children under two years are under-represented in these analyses because 
of the difficulty of obtaining clean catch samples in this age group. However, we found our rule to be 
diagnostically accurate in children under three years able to provide a clean catch urine sample. Our 
secondary care experience, and a recent report describing a bladder stimulation technique for infants,23 
suggest that when sufficient time, space and personnel are available, clean catch sampling is possible in 
most young children.  
We mitigated the impact of false positive urine cultures (arising as a result of asymptomatic bacteriuria24 or 
contamination) using three design features. First, children were only eligible if experiencing constitutional 
and/or urinary symptoms; second, the rule was developed only using clean catch samples; and third, we 
used a single research laboratory, which used methods superior to NHS laboratories to distinguish 
contaminated urine. Incorporation bias could have inflated the AUROC for step two using the US definition 
of UTI since dipstick leucocytes were used as both an index test and within reference standard definition. 
Results in context with other studies 
One systematic review of eight primary studies (7892 children),25 and five primary studies10 11 26 27 28 of a 
further 18,796 children (with only one26 conducted in GP surgeries) have assessed UTI prevalence and the 
diagnostic value of clinical symptoms and signs in children <5 years.29 These found similar UTI prevalence 
and showed abdominal pain, back pain, dysuria, frequency, and new-onset urinary incontinence were 
positively associated with UTI.25 Stridor, audible wheeze, circumcision, temperature <39°C with a source, 
abnormal chest sounds, chest crackles, age under three years, not feeling hot, and rapid breathing were 
inversely associated with UTI. The largest study, which included 16,000 children presenting to the CED, 
derived a complex model based on 27 symptoms and signs, with an AUROC of 0.80 (95% CI 0.78 to 0.82).27 
The only previous study to recruit from GP surgeries found that younger age, urinary frequency and 
pain/crying on passing urine were associated with UTI, but had insufficient children with UTI to develop a 
clinical rule.26 Previous investigation of malodorous urine has shown conflicting results,28 30 but our study 
strongly supports its diagnostic value. Dipstick testing has been considered diagnostically unhelpful in 
young children.5 
Clinical and research implications 
In keeping with recently updated US guidelines,6 our results support a ‘risk-based’ approach to the 
identification of children for investigation of UTI. Pain or crying while passing urine, smelly urine, previous 
UTI, absence of severe cough, severe illness, abdominal tenderness, and absence of ear abnormalities can 
be used for deciding which children to urine sample (step 1) and dipstick results to improve specificity for 
antibiotic treatment (step 2). For both steps, increasing diagnostic sensitivity can be achieved by increasing 
urine sampling rates, which may not be feasible or affordable. Precisely how these results are used is likely 
to depend on clinician preference. Some clinicians may wish to use these as “risk factors” to feed into 
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clinical judgement. Others may prefer to use a “check list” approach and use the points-based clinical rules 
(Figure 2, which can be used without computer assistance) which focus attention on predictive factors 
rather than those (such as fever) with poor diagnostic utility. Clinicians concerned about over-diagnosis and 
treatment could select a higher specificity threshold, while higher sensitivity thresholds would reduce 
under-diagnosis. When the rule is used, it should supplement not replace clinical judgement. 
Further research is needed to distinguish pathogens from contamination and asymptomatic bacteriuria.24 
Given the expense of an external validation study, and the low rates of routine urine sampling (which 
render routine datasets unsuitable), we consider the most cost-effective future research strategy would be 
to assess the impact of the DUTY clinical rule on clinical behaviour and patient outcome in a randomised 
trial, and that the strongest design would integrate the presentation of the coefficient-based clinical rule 
within routine clinical care, probably via electronic medical records.  
CONCLUSIONS  
Our rule can be used to enhance current clinical practice in the identification of young children for non-
invasive urine sampling in primary care. Fever should not be used to stratify UTI probability and dipstick 
testing can be used to improve specificity for empiric antibiotic treatment in this population.  
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Table 1. Children’s characteristics and crude odds ratio for associations with UTI. 
Demographics and index 
tests* 
 N (%)a UTI positive 
(%)b 
Crude OR 
(95% CI) 
Gender Male 1267 (46.2%) 13 (1.0%) 1 (ref) 
 Female 1473 (53.8%) 47 (3.2%) 3.18 (1.71,5.90) 
Age of child <6 months 34 (1.2%) 1 (2.9%) 1.13 (0.15,8.77) 
 6 to <12 months 54 (2.0%) 3 (5.6%) 2.19 (0.62,7.77) 
 1 to <2 years 91 (3.3%) 2 (2.2%) 0.84 (0.19,3.70) 
 2 to <3 years 612 (22.3%) 16 (2.6%) 1 (ref) 
 3 to <4 years 1073 (39.2%) 21 (2.0%) 0.74 (0.39,1.44) 
 4 years plus 876 (32.0%) 17 (1.9%) 0.74 (0.37,1.47) 
Clinician diagnosis prior 
to dipstick 
Not UTI certain / v. certain 1149 (41.9%) 6 (0.5%) 0.28 (0.12,0.69) 
Not UTI fairly certain / uncertain 1417 (51.7%) 26 (1.8%) 1(ref) 
UTI fairly  to very certain  168 (6.1%) 28 (16.7%) 10.75 (6.13,18.8) 
Missing 6 (0.2%) 0 (0.0%)  
Pain/crying when passing 
urine* 
No problem 2234 (81.5%) 22 (1.0%) 1 (ref) 
Slight problem 182 (6.6%) 6 (3.3%) 2.97 (1.21,7.29) 
 Moderate problem 128 (4.7%) 12 (9.4%) 9.01 (4.45,18.2) 
 Severe problem 51 (1.9%) 15 (29.4%) 36.30 (17.81,74.0) 
 Missing/not known 145 (5.3%) 5 (3.4%)  
Smelly urine* No problem 2108 (76.9%) 20 (0.9%) 1 (ref) 
 Slight problem 174 (6.4%) 10 (5.7%) 5.87 (2.76,12.5) 
 Moderate problem 179 (6.5%) 16 (8.9%) 9.46 (4.93,18.2) 
 Severe problem 51 (1.9%) 10 (19.6%) 23.5 (10.6,52.3) 
 Missing/not known 228 (8.3%) 4 (1.8%)  
Cough* No problem 773 (28.2%) 24 (3.1%) 1 (ref) 
 Slight problem 556 (20.3%) 16 (2.9%) 0.93 (0.48,1.76) 
 Moderate problem 829 (30.3%) 17 (2.1%) 0.66 (0.35,1.23) 
 Severe problem 579 (21.1%) 3 (0.5%) 0.16 (0.05,0.54) 
 Missing/not known 3 (0.1%) 0 (0.0%)  
Previous UTI* No 2449 (89.4%) 43 (1.8%) 1 (ref) 
 Yes 177 (6.5%) 12 (6.8%) 3.81 (1.99,7.31) 
 Missing/not known 114 (4.2%) 5 (4.4%)  
Clinician global 
impression of illness 
severity (0-10)* 
0-1 989 (36.1%) 14 (1.4%) 1 (ref) 
2 739 (27.0%) 14 (1.9%) 1.35 (0.64,2.85) 
3 531 (19.4%) 14 (2.6%) 1.89 (0.89,4.00) 
4-5 363 (13.2%) 12 (3.3%) 2.39 (1.09,5.21) 
6 or more 115 (4.2%) 6 (5.2%) 3.85 (1.45,10.21) 
missing 3 (0.1%) 0 (0.0%)  
Abdominal exam: any 
tenderness* 
No 2237 (81.6%) 46 (2.1%) 1 (ref) 
Yes 63 (2.3%) 8 (12.7%) 7.34 (3.33,16.19) 
 Missing 440 (16.1%) 6 (1.4%)  
Ear exam: any acute 
abnormality* 
No 1783 (65.1%) 50 (2.8%) 1 (ref) 
Yes 635 (23.2%) 4 (0.6%) 0.23 (0.08,0.64) 
 Missing 322 (11.8%) 6 (1.9%)  
Dipstick: leukocytes* Negative 2272 (82.9%) 17 (0.7%) 1 (ref) 
 Trace 154 (5.6%) 6 (3.9%) 5.40 (2.10,13.9) 
 + 110 (4.0%) 2 (1.8%) 2.47 (0.56,10.8) 
 ++ 148 (5.4%) 19 (12.8%) 19.61 (9.95,38.6) 
 +++ 48 (1.8%) 16 (33.3%) 66.6 (30.9,143.3) 
 Missing 8 (0.3%) 0 (0.0%)  
Dipstick: nitrites* Negative 2658 (97.0%) 35 (1.3%) 1 (ref) 
 Positive 74 (2.7%) 25 (33.8%) 38.4 (21.4,68.9) 
 Missing 8 (0.3%) 0 (0.0%)  
Dipstick: blood* Negative 2297 (83.8%) 29 (1.3%) 1 (ref) 
 Non-heme 246 (9.0%) 8 (3.3%) 2.64 (1.19,5.84) 
 Heme trace 50 (1.8%) 6 (12.0%) 10.70 (4.23,27.08) 
 Heme + 67 (2.4%) 4 (6.0%) 4.98 (1.70,14.60) 
 16 
Demographics and index 
tests* 
 N (%)a UTI positive 
(%)b 
Crude OR 
(95% CI) 
 Heme ++ or +++ 72 (2.6%) 13 (18.1%) 17.29 (8.56,34.94) 
 Missing 8 (0.3%) 0 (0.0%)  
* Index tests independently associated with UTI in multivariable models. Missing values were assigned to the modal category for 
crude OR. 
a All children column gives the percentage of observations within that category 
b Children with UTI column gives the percentage of positives relative to the number of observations within that category
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Table 2. Coefficient based modelsa for symptoms and signs; symptoms, signs and dipstick results; 
including results based on multiple imputation   
        Symptom and sign model     Symptom, sign and dipstick model 
Index tests Adjusted  ORa 
(95 % CI)b 
MIc adjusted ORa 
(95% CI) 
Adjusted  ORa 
(95 % CI)b 
MIc adjusted ORa 
(95% CI) 
Pain/crying when passing urine     
No problem 1 (ref) 1 (ref) 1 (ref) 1 (ref) 
Slight problem 1.56 (0.68,3.61) 1.73 (0.73,4.06) 1.01 (0.37,2.80) 1.16 (0.41,3.24) 
Moderate problem 4.58 (2.27,9.25) 4.80 (2.30,10.04) 2.68 (1.16,6.18) 2.87 (1.21,6.82) 
Severe problem 14.32 (6.81,30.11) 15.81 (7.37,33.89) 9.64 (3.92,23.69) 10.33 (4.11,25.96) 
Smelly urine     
No problem 1 (ref) 1 (ref) 1 (ref) 1 (ref) 
Slight problem 4.08 (2.00,8.33) 4.28 (2.02,9.05) 2.97 (1.29,6.85) 3.16 (1.32,7.59) 
Moderate problem 5.00 (2.64,9.48) 5.14 (2.60,10.19) 4.16 (2.02,8.57) 4.34 (2.00,9.39) 
Severe problem 8.49 (3.74,19.26) 8.76 (3.76,20.41) 4.13 (1.51,11.31) 4.44 (1.57,12.54) 
Previous UTI     
No 1 (ref) 1 (ref) 1 (ref) 1 (ref) 
Yes 2.71 (1.39,5.27) 2.66 (1.34,5.26) 2.39 (1.12,5.11) 2.36 (1.10,5.03) 
Cough     
No problem 1 (ref) 1 (ref) 1 (ref) 1 (ref) 
Slight problem 1.28 (0.67,2.45) 1.32 (0.68,2.55) 1.27 (0.59,2.72) 1.30 (0.60,2.81) 
Moderate problem 1.31 (0.69,2.48) 1.38 (0.72,2.68) 1.95 (0.95,4.00) 2.04 (0.98,4.22) 
Severe problem 0.28 (0.08,0.93) 0.29 (0.09,0.97) 0.36 (0.09,1.48) 0.36 (0.09,1.51) 
Clinician global impression of illness severity (0-10)   
0-1 1 (ref) 1 (ref) 1 (ref) 1 (ref) 
2 1.97 (0.95,4.12) 1.98 (0.93,4.19) 2.14 (0.93,4.91) 2.13 (0.92,4.97) 
3 2.66 (1.28,5.54) 2.72 (1.28,5.81) 2.65 (1.16,6.07) 2.63 (1.13,6.14) 
4-5 3.57 (1.61,7.91) 3.87 (1.72,8.73) 2.96 (1.18,7.42) 3.24 (1.28,8.24) 
6 or more 6.84 (2.52,18.56) 7.24 (2.59,20.25) 5.80 (1.81,18.60) 6.28 (1.92,20.61) 
Abdominal exam: any tenderness     
No 1 (ref) 1 (ref) 1 (ref) 1 (ref) 
Yes 2.40 (1.03,5.61) 2.24 (0.95,5.25) 1.34 (0.40,4.45) 1.18 (0.35,3.94) 
Ear exam: any acute abnormality     
No 1 (ref) 1 (ref) 1 (ref) 1 (ref) 
Yes 0.30 (0.11,0.83) 0.27 (0.10,0.74) 0.46 (0.18,1.22) 0.40 (0.15,1.09) 
Dipstick: leukocytes     
Negative   1 (ref) 1 (ref) 
Trace   1.81 (0.68,4.81) 1.78 (0.66,4.78) 
+   0.70 (0.16,3.13) 0.66 (0.14,3.12) 
++   5.27 (2.52,11.04) 5.19 (2.45,10.98) 
+++   10.45 (4.11,26.53) 10.36 (3.94,27.26) 
Dipstick: nitrites     
Negative   1 (ref) 1 (ref) 
Positive   5.25 (2.56,10.77) 5.37 (2.58,11.19) 
Dipstick: blood     
Negative   1 (ref) 1 (ref) 
Non-heme   0.88 (0.36,2.17) 0.89 (0.35,2.21) 
Heme trace   4.16 (1.34,12.85) 4.08 (1.28,13.05) 
Heme +   2.65 (0.87,8.03) 2.84 (0.92,8.79) 
Heme ++ or +++   1.71 (0.65,4.51) 1.74 (0.64,4.73) 
Area under ROC curve (95% CI)d 0.892 (0.84,0.94) 0.899 (0.85,0.95) 0.926 (0.89,0.96) 0.933 (0.90,0.97) 
Validated area under ROC curve e 0.871 0.876 0.904 0.903 
Calibration slopee 0.865 0.871 0.832 0.832 
a Odds ratios calculated using shrunken estimates from the bootstrap internal validation calibration slope; b Missing values coded to 
modal category; c MI: multiple imputation; d Calculated without internal validation. e Calculated from the bootstrap internal 
validation  
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Table 3. Diagnostic test characteristics (95% CI) of coefficient based modelsa for a range of sensitivity cutpoints, using symptoms and signs model 
(upper part of table for urine sampling and antibiotic treatment) and the symptoms, signs and dipstick model (lower part of table for antibiotic 
treatment). 
Linear predictor 
cutpoint – 
shrunken 
coefficients (≥)b 
Linear predictor 
cutpoint – 
unshrunken 
coefficients (≥)b Sensitivity Specificity 
Positive Predictive 
Value 
Negative Predictive 
Value 
Percentage of children clinical 
rule positive 
Symptom and sign model 
  
Percentage urine 
sampled/antibiotic treatedc 
-0.504 -0.195 20.0% (11.7%, 32.0%) 99.8% (99.5%, 99.9%) 66.7% (42.9%, 84.2%) 98.2% (97.7%, 98.7%) 0.7% (0.4%, 1.0%) 
-1.092 -0.87 30.0% (19.8%, 2.7%) 99.5% (99.1%, 99.7%) 56.3% (39.0%, 72.1%) 98.4% (97.9%, 98.9%) 1.2% (0.8%, 1.6%) 
-1.813 -1.698 40.0% (28.5%, 52.8%) 98.2% (97.6%, 98.6%) 32.9% (23.1%, 44.4%) 98.7% (98.1%, 99.0%) 2.7% (2.1%, 3.3%) 
-2.059 -1.98 50.0% (37.6%, 62.4%) 97.5% (96.9%, 98.1%) 31.3% (22.8%, 41.2%) 98.9% (98.4%, 99.2%) 3.5% (2.9%, 4.3%) 
-2.372 -2.34 60.0% (47.2%, 71.5%) 96.3% (95.5%, 97.0%) 26.7% (19.9%, 34.7%) 99.1% (98.6%, 99.4%) 4.9% (4.2%, 5.8%) 
-2.729 -2.75 70.0% (57.3%, 80.2%) 94.6% (93.7%, 95.4%) 22.6% (17.1%, 29.1%) 99.3% (98.9%, 99.6%) 6.8% (5.9%, 7.8%) 
-3.396 -3.515 80.0% (68.0%, 88.3%) 88.3% (87.0%, 89.4%) 13.3% (10.1%, 17.2%) 99.5% (99.1%, 99.7%) 13.2% (12.0%, 14.5%) 
-3.717 -3.884 85.0% (73.6%, 92.0%) 83.9% (82.4%, 85.2%) 10.6% (8.1%, 13.6%) 99.6% (99.2%, 99.8%) 17.6% (16.2%, 19.1%) 
-4.567 -4.86 93.3% (83.5%, 97.5%) 61.0% (59.1%, 62.8%) 5.1% (3.9%, 6.6%) 99.8% (99.4%, 99.9%) 40.2% (38.4%, 42.0%) 
-5.299 -5.7 96.7% (87.6%, 99.2%) 37.8% (35.9%, 39.6%) 3.4% (2.6%, 4.3%) 99.8% (99.2%, 100.0%) 63.0% (61.2%, 64.8%) 
-6.138 -6.664 100%  15.7% (14.4%, 17.1%) 2.6% (2.0%, 3.3%) 100%  84.6% (83.2%, 85.9%) 
Symptom, sign and dipstick model   Percentage antibiotic treatedd 
0.801 1.43 20.0% (11.7%, 32.0%) 99.9% (99.7%, 100.0%) 85.7% (57.3%, 96.4%) 98.2% (97.7%, 98.7%) 0.5% (0.3%, 0.9%) 
-0.122 0.321 40.0% (28.5%, 52.8%) 99.9% (99.7%, 100.0%) 88.9% (70.7%, 96.4%) 98.7% (98.2%, 99.0%) 1.0% (0.7%, 1.4%) 
-1.346 -1.15 60.0% (47.2%, 71.5%) 99.3% (98.8%, 99.5%) 64.3% (51.0%, 75.7%) 99.1% (98.7%, 99.4%) 2.0% (1.6%, 2.6%) 
-3.114 -3.275 80.0% (68.0%, 88.3%) 93.8% (92.9%, 94.7%) 22.5% (17.4%, 28.6%) 99.5% (99.2%, 99.7%) 7.8% (6.8%, 8.8%) 
-3.700 -3.98 83.3% (71.7%, 90.8%) 88.3% (87.0%, 89.5%) 13.8% (10.6%, 17.7%) 99.6% (99.2%, 99.8%) 13.2% (12.0%, 14.6%) 
-4.746 -5.237 96.7% (87.6%, 99.2%) 66.3% (64.5%, 68.1%) 6.0% (4.7%, 7.7%) 99.9% (99.6%, 100.0%) 35.0% (33.3%, 36.8%) 
-5.235 -5.825 98.3% (89.1%, 99.8%) 53.1% (51.2%, 54.9%) 4.5% (3.5%, 5.7%) 99.9% (99.5%, 100.0%) 48.1% (46.2%, 49.9%) 
-5.955 -6.69 100%  29.5% (27.8%, 31.2%) 3.1% (2.4%, 3.9%) 100%  71.2% (69.4%, 72.8%) 
a Results based on models using multiple imputation to deal with missing values 
b Derived from the coefficient based models using multiple imputation where the coefficients are listed within Web Table 5  
c Percentage of children who would be at or above this threshold assuming that all children had a urine sample  
d Percentage of children who would be at or above this threshold assuming that all children had a urine sample and dipstick test 
For comparison, ‘clinician diagnosis’ sensitivity was 46.6% and specificity 94.7% 
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Figure 1. ROC curve for multiple imputation, coefficient-based models for clinician diagnosis 
(dashed line), symptoms and signs only (solid line) and symptoms, signs and dipstick (dotted line). 
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Figure 2. DUTY (Diagnosis of Urinary Tract infection in Young) Children Clean Catch Criteria
How to use the DUTY Clean Catch Urine Criteria 
1. The DUTY Clean Catch Urine Criteria are for children in whom a clean catch sample is possible. 
2. Urinary tract infection (UTI) was defined as ≥105 Colony Forming Units (CFU)/mL of a single or 
predominant uropathogen cultured from a clean catch urine specimen 
3. Table A: Use the symptoms and signs to decide if a clean catch urine should be collected/antibiotics 
given (≥5 points or can be operationalised as ‘any three of the five’ symptoms and signs has been 
shown to be cost effective). Clinicians concerned about over-diagnosis and treatment can select a 
higher specificity (at least six points) threshold. Higher sensitivity thresholds (e.g. ≥3 points or ≥4 
points) would reduce under-diagnosis, but these thresholds have not been shown to be cost effective. 
4. It is not clear which of the following possible antibiotic treatment strategies is most cost effective: (i) 
immediate presumptive treatment of all sampled children; (ii) immediate dipstick guided treatment; or 
(iii) laboratory guided (delayed) treatment. 
5. For children urine sampled at the ≥5 point threshold, the probability of UTI will be 18% (Web Table 3 
(upper)). Although not demonstrably cost-effective, dipstick testing can raise or lower this probability 
(see Table B).  
6. Table B: Refer to Web Table 3 (lower) for probability of UTI with total score 
7. Consider advising all (urine and non-urine sampled) children’s parents to seek medical advice if their 
child gets worse  
8. The DUTY Clean Catch Urine Criteria are designed to supplement and not replace clinical judgement 
 
Table A: Should I get a urine sample?  
Clinical characteristic (present/absent)a POINTSb 
  
Symptoms and signs To guide urine collection 
Pain/crying passing urinec  2 
Smelly urinec  2 
Previous UTIc 1 
Absence of severe coughd 2 
Severe illness presente 2 
 
Collect clean catch urine if symptoms and signs points 
total ≥5 “any three of the five” 
 
Table B. Should I give antibiotic treatment? 
Clinical characteristic (present/absent)a POINTS 
  
Symptoms, signs and dipstick To guide antibiotic treatment 
Pain/crying passing urinec  2 
Smelly urinec  2 
Previous UTIc 1 
Absence of severe coughd 2 
Severe illness presente 2 
Dipstick: Leukocytes positive 2 
Dipstick: Nitrites positive 3 
Dipstick: Blood positive 1 
  
a Clinical characteristic wording as used in study Case Report Form and reported by parent/clinician unless stated otherwise 
b Refer to Web Table 3 (upper) for probability of UTI with total score  
c Parents were asked to report presence/absence 
d Parents were asked to grade presence of cough as no problem, slight problem, moderate problem or severe problem  
e Score of ≥6 on the clinician global illness severity scale with range 0 (child completely well) to 10 (child extremely unwell). 
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